606 related articles for article (PubMed ID: 34253199)
1. Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study.
Moazzeni SS; Hizomi Arani R; Deravi N; Hasheminia M; Khalili D; Azizi F; Hadaegh F
Cardiovasc Diabetol; 2021 Jul; 20(1):141. PubMed ID: 34253199
[TBL] [Abstract][Full Text] [Related]
2. Three-year weight change and risk of all-cause, cardiovascular, and cancer mortality among Iranian adults: over a decade of follow-up in the Tehran Lipid and Glucose Study.
Deravi N; Moazzeni SS; Hasheminia M; Hizomi Arani R; Azizi F; Hadaegh F
BMC Public Health; 2022 Sep; 22(1):1762. PubMed ID: 36114528
[TBL] [Abstract][Full Text] [Related]
3. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study.
Kabootari M; Hasheminia M; Azizi F; Mirbolouk M; Hadaegh F
Cardiovasc Diabetol; 2020 Mar; 19(1):41. PubMed ID: 32228577
[TBL] [Abstract][Full Text] [Related]
4. The impact of triglyceride-glucose index on incident cardiovascular events during 16 years of follow-up: Tehran Lipid and Glucose Study.
Barzegar N; Tohidi M; Hasheminia M; Azizi F; Hadaegh F
Cardiovasc Diabetol; 2020 Sep; 19(1):155. PubMed ID: 32993633
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.
Nunes AP; Iglay K; Radican L; Engel SS; Yang J; Doherty MC; Dore DD
Diabetes Obes Metab; 2017 Oct; 19(10):1425-1435. PubMed ID: 28497592
[TBL] [Abstract][Full Text] [Related]
6. Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study.
Kabootari M; Asgari S; Ghavam SM; Abdi H; Azizi F; Hadaegh F
J Transl Med; 2021 Jun; 19(1):277. PubMed ID: 34193200
[TBL] [Abstract][Full Text] [Related]
7. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Hanefeld M; Traylor L; Gao L; Landgraf W
Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
[TBL] [Abstract][Full Text] [Related]
8. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.
Li Y; Hu Y; Ley SH; Rajpathak S; Hu FB
Diabetes Care; 2014 Nov; 37(11):3106-13. PubMed ID: 25150157
[TBL] [Abstract][Full Text] [Related]
9. Long-term incidence of cardiovascular outcomes in the middle-aged and elderly with different patterns of physical activity: Tehran lipid and glucose study.
Naseri P; Amiri P; Masihay-Akbar H; Jalali-Farahani S; Khalili D; Azizi F
BMC Public Health; 2020 Nov; 20(1):1654. PubMed ID: 33148219
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
11. Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study.
Hadaegh F; Derakhshan A; Mozaffary A; Hasheminia M; Khalili D; Azizi F
PLoS One; 2016; 11(3):e0149780. PubMed ID: 26930192
[TBL] [Abstract][Full Text] [Related]
12. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
13. The association of parity/live birth number with incident type 2 diabetes among women: over 15 years of follow-up in The Tehran Lipid and Glucose Study.
Moazzeni SS; Hizomi Arani R; Asgari S; Azizi F; Hadaegh F
BMC Womens Health; 2021 Oct; 21(1):378. PubMed ID: 34715851
[TBL] [Abstract][Full Text] [Related]
14. Low-carbohydrate diet and cardiovascular diseases in Iranian population: Tehran Lipid and Glucose Study.
Farhadnejad H; Asghari G; Teymoori F; Tahmasebinejad Z; Mirmiran P; Azizi F
Nutr Metab Cardiovasc Dis; 2020 Apr; 30(4):581-588. PubMed ID: 32008914
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.
Fu AZ; Qiu Y; Radican L; Yin DD; Mavros P
Cardiovasc Diabetol; 2010 Apr; 9():15. PubMed ID: 20409333
[TBL] [Abstract][Full Text] [Related]
16. Resting heart rate and the risk of incident type 2 diabetes mellitus among non-diabetic and prediabetic Iranian adults: Tehran lipid and glucose study.
Moazzeni SS; Karimi Toudeshki K; Ghorbanpouryami F; Hasheminia M; Azizi F; Pishgahi M; Hadaegh F
BMC Public Health; 2023 Oct; 23(1):2112. PubMed ID: 37891510
[TBL] [Abstract][Full Text] [Related]
17. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
18. Sex-specific clinical outcomes of impaired glucose status: A long follow-up from the Tehran Lipid and Glucose Study.
Parizadeh D; Rahimian N; Akbarpour S; Azizi F; Hadaegh F
Eur J Prev Cardiol; 2019 Jul; 26(10):1080-1091. PubMed ID: 30862232
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
20. Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study.
Kabootari M; Asgari S; Mansournia MA; Khalili D; Valizadeh M; Azizi F; Hadaegh F
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
